CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells  by Zhang, Jing-Min et al.
lable at ScienceDirect
Biochemical and Biophysical Research Communications 459 (2015) 252e258Contents lists avaiBiochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate/ybbrcCD109 attenuates TGF-b1 signaling and enhances EGF signaling in
SK-MG-1 human glioblastoma cells
Jing-Min Zhang a, b, 1, Yoshiki Murakumo a, c, *, 1, Sumitaka Hagiwara a, Ping Jiang a, d,
Shinji Mii a, Emir Kalyoncu a, Shoji Saito a, Chikage Suzuki a, Yasutaka Sakurai c,
Yoshiko Numata c, Toshimichi Yamamoto e, Masahide Takahashi a
a Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan
b Department of Pharmacognosy, Jilin University School of Pharmacy, Changchun, PR China
c Department of Pathology, Kitasato University School of Medicine, Sagamihara, Japan
d The Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics, Ministry of Health, Beijing, PR China
e Legal Medicine and Bioethics, Nagoya University Graduate School of Medicine, Nagoya, Japana r t i c l e i n f o
Article history:
Received 8 February 2015
Available online 25 February 2015
Keywords:
CD109
EGF signaling
Glycosylation
SK-MG-1 glioblastoma cells
TGF-b1 signaling* Corresponding author. Department of Pathology,
Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara,
Fax: þ81 42 778 9124.
E-mail address: murakumo@med.kitasato-u.ac.jp (
1 These authors contributed equally to this study.
http://dx.doi.org/10.1016/j.bbrc.2015.02.093
0006-291X/© 2015 The Authors. Published by Elseviera b s t r a c t
CD109 is a glycosylphosphatidylinositol-anchored cell surface protein that is frequently detected in
squamous cell carcinomas. CD109 is a negative regulator of TGF-b1 signaling in human keratinocytes,
and the N-terminal fragment of CD109 secreted from cells after cleavage by the furin protease is
important for modulating TGF-b1 signaling. Previously, we found that CD109 is expressed in human
glioblastoma cells; however, the role of CD109 in glioblastoma cells is not established. Here, we describe
the effects of CD109 in human glioblastoma cell lines. Three glioblastoma cell lines, SK-MG-1, U251MG
and MG178, were tested and CD109 overexpression attenuated TGF-b1 signaling and enhanced EGF
signaling in SK-MG-1, but not in U251MG or MG178. The N-terminal CD109 fragment in SK-MG-1 was
hyperglycosylated compared with that in MG178 or U251MG. The conditioned medium of CD109-
overexpressing SK-MG-1, containing the secreted N-terminal CD109, had a negative effect on TGF-b1
signaling in wild-type SK-MG-1 and MG178, whereas it did not show any effect on EGF signaling. In
addition, cell surface CD109 interacts with EGF receptor in SK-MG-1 overexpressing CD109, and exhibited
enhanced cell migration and invasion. These ﬁndings suggest that CD109 attenuates TGF-b1 signaling
and enhances EGF signaling in SK-MG-1 cells and that the membrane-anchored CD109 may play major
roles in the EGF signaling pathway.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
CD109 is a glycosylphosphatidylinositol (GPI)-linked glycopro-
tein located on the plasma membrane [1,2]. It has been studied as a
cell surface antigen expressed on some types of normal hemato-
poietic cells and hematopoietic tumor cells [1,3,4]. CD109 mRNA is
highly expressed in several cell lines derived from human tumors,
including lung squamous cell carcinomas (SCCs), melanomas and
glioblastomas [5]. In tumor tissues, CD109 was immunohis-
tochemically detected in SCCs, urothelial carcinomas, malignantKitasato University School of
Kanagawa 252-0374, Japan.
Y. Murakumo).
Inc. This is an open access article umelanomas, basal-like breast carcinomas and epithelial sarcomas
[6e12]. CD109 overexpression promotes accelerated cell growth in
oral SCC cells. In addition, oral dysplastic epithelia expressing high
levels of CD109 progressed to SCC within 3 years at a high fre-
quency, and a strong correlation was detected between CD109
expression and prognosis in soft tissue sarcomas [10,12]. These
ﬁndings suggest that CD109 might be involved in the development
of several human tumors.
CD109 is involved in the TGF-b1 signaling pathway as a negative
regulator via formation of a receptor complex with TGF-b receptor I
and II in human keratinocytes [13]. CD109 promotes TGF-b receptor
internalization and degradation by regulation of SMAD7 and
SMURF2 activity in ubiquitin-mediated proteolysis [14,15]. It was
also reported that proteolytic processing of CD109 by furin or
mesotrypsin is required for its function in cultured cells [16,17].
After cleavage by furin, a proportion of N-terminal 180-kDander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the cell surface. The C-terminal 25-kDa fragment is anchored to GPI
on the cell surface. The secreted fragment of CD109 is important for
the regulation of TGF-b1 signaling [16]. CD109 is also associated
with several nontumorigenic disorders in human and mouse.
Aberrant CD109 release from dermal keratinocytes might be a
cause of TGF-b1 receptor downregulation and TGF-b1 signal
attenuation in psoriasis [18]. CD109 overexpression in the mouse
epidermis reduced the inﬂammatory response and improved
collagen organization during wound healing, showing decreased
SMAD2/3 phosphorylation [19]. CD109-deﬁcient mice showed that
CD109 is necessary for normal growth of the epidermis and ap-
pendages [20]. However, the biological signiﬁcance of CD109 in
tumor cells is still unclear.
In this study, we demonstrated that CD109 attenuates TGF-b1
signaling and facilitates EGF signaling in SK-MG-1 human glio-
blastoma cells, but not U251MG or MG178 cells. The present ﬁnd-
ings demonstrate the diversity of CD109 function in human tumor
cells.
2. Materials and methods
2.1. Plasmid constructions
Construction of the expression vector pcDNA3.1(þ)/FLAG-
CD109 possessing a FLAG-tagged full-length human CD109
(FLAG-CD109) cDNA was described previously [6]. The retrovirus
expression vector pRetroQ/FLAG-CD109 for FLAG-CD109 expres-
sion was constructed using pRetroQ (Takara).
2.2. Cell culture and reagents
Human glioblastoma cell lines, SK-MG-1, MG178 and U251MG
were maintained in DMEM supplemented with 8% FBS. To generate
FLAG-CD109 and control transfectants, SK-MG-1 and U251MG cells
were transfected with pcDNA3.1(þ)/FLAG-CD109 or pcDNA3.1(þ)/
FLAG using Lipofectamine 2000 transfection reagent (Invitrogen).
Forty-eight hours after transfection, cells were incubated in selec-
tionmedia containing 400 mg/ml G418 (Invitrogen) for 2weeks, and
several stable transfectants were obtained. To produce FLAG-CD109
retroviral supernatants, GP2-293 packaging cells (Takara) were co-
transfected with pVSV-G (Takara) and either pRetroQ/FLAG-CD109
or control vector possessing GFP cDNA using FuGENE 6 transfection
reagent (Roche). The medium was replaced after 24 h, and virus-
containing supernatants were harvested 48 h post-transfection
and used to infect MG178 cells. The infected cells were selected
in puromycin-containing media (1 mg/ml) for 1 week.
2.3. Signaling analysis
To analyze TGF-b1 or EGF signaling, cells were serum-starved
for 2 h and stimulated with 50 pM TGF-b1 (PeproTech) or 5 ng/ml
EGF (Invitrogen) for the indicated periods. To analyze the effect of
secreted CD109 on TGF-b1 or EGF signaling, SK-MG-1-CD109, SK-
MG-1-control, MG178-CD109, and MG178-control cells were
grown until conﬂuent and then incubated for another day. The
conditioned media of the transfectants were clariﬁed by centrifu-
gation and used for signaling analyses. Wild-type SK-MG-1 and
MG178 cells were serum-starved and stimulated with TGF-b1 or
EGF in the clariﬁed conditioned media.
2.4. Antibodies
Mouse monoclonal anti-CD109 (C-9) antibody was purchased
from Santa Cruz Biotechnology. Mouse monoclonal anti-CD109(11H3) antibody was purchased from Immuno-Biological Labora-
tories. Mouse monoclonal anti-FLAG M2 and -b-actin antibodies
were purchased from Sigma-Aldrich. Rabbit monoclonal anti-EGFR
and -phospho-EGFR (pEGFR) antibodies were from Epitomics.
Rabbit polyclonal anti-pAKT and -pERK antibodies and rabbit
monoclonal anti-SMAD2 and -pSMAD2 antibodies were from Cell
Signaling Technology. Goat anti-rabbit IgG and anti-mouse IgG
secondary antibodies conjugated with Alexa 488 or Alexa 594,
respectively, were from Invitrogen. The epitope positions on FLAG-
CD109 for anti-CD109 and -FLAG antibodies are illustrated in
Fig. 1A.2.5. Glycosylation analyses
For glycosylation inhibition, FLAG-CD109-overexpressing cells
were treated with 2 mg/ml tunicamycin for 48 h and used for
western blotting (Supplementary Doc S1). For deglycosylation an-
alyses, FLAG-CD109-overexpressing cells were subjected to
immunoprecipitation using anti-FLAG antibody (Supplementary
Doc S1). Precipitated FLAG-CD109 was treated with PNGase F
(Enzymatic Protein deglycosylation kit, Sigma-Aldrich) for 3 h at
37 C, boiled in 1  SDS sample buffer, and subjected to western
blotting.2.6. Wound-healing assay
Cells were seeded on 35 mm dishes, and conﬂuent cells were
scratched with a disposable plastic pipette tip and allowed to
migrate towards the wound. Images were captured with a CCD
digital camera (Olympus) coupled to an inverted microscope
(Olympus).2.7. In vitro cell migration and invasion assays
2.5  104 cells stained with CellTracker Green CMEDA (Invi-
trogen) were seeded in the top chamber of HTS FluoroBlok Inserts
for migration assay or HTS FluoroBlok Inserts coated with matrigel
matrix for invasion assay (8 mm pore size, BD Biosciences) in 200 ml
DMEM containing 0.1% FBS. Five hundred microliters of DMEM
with 0.1% FBS was added to the bottom chamber. Cells were
allowed to migrate for 6 h or invade for 22 h, and cells that had
migrated or invaded under the membrane were ﬁxed in 10%
formaldehyde. Fluorescence images were captured with a CCD
camera (Olympus), and the cells were counted under a ﬂuorescence
microscope in ﬁve randomly selected ﬁelds.3. Results
3.1. CD109 attenuates TGF-b1 signaling and facilitates EGF
signaling in SK-MG-1 cells but not in MG178 and U251MG cells
Transfectants overexpressing FLAG-CD109 were generated us-
ing the three glioblastoma cell lines, SK-MG-1, MG178 and
U251MG, and TGF-b1 signaling in these and control cells was
assessed bywestern blotting. As expected, SMAD2 phosphorylation
after TGF-b1 stimulation was attenuated in CD109-overexpressing
SK-MG-1 compared with control cells (Fig. 1C). In contrast,
SMAD2 phosphorylationwas not affected by CD109 overexpression
in MG178 or U251MG. EGF signaling in these cells was then
analyzed. After EGF stimulation, phosphorylation of EGFR, AKT, and
ERKwas enhanced and sustained in CD109-overexpressing SK-MG-
1 compared with control cells, whereas it was not affected by
CD109 overexpression in MG178 and U251MG (Fig. 1D).
Fig. 1. CD109 attenuates TGF-b1 signaling and enhances EGF signaling in SK-MG-1 cells but not in MG178 and U251MG cells. (A) Protein structure of FLAG-CD109, and epitope
positions of antibodies used in this study. FLAG, C-9 and 11H3 indicate anti-FLAG, anti-CD109 (C-9), and anti-CD109 (11H3) antibodies, respectively. (B) A scheme of CD109
processing in cells. Cytosolic uncleaved CD109 (190 kDa) is glycosylated and cleaved by furin, resulting in a C-terminal fragment (25 kDa) anchoring to GPI on the cell surface, and an
N-terminal fragment (180 kDa) partially secreted with a fraction binding to the C-terminal fragment. (C, D) SK-MG-1, MG178, and U251MG cells with and without FLAD-CD109
overexpression were stimulated with 50 pM TGF-b1 (C) or 5 ng/ml EGF (D) and downstream signaling was analyzed by western blotting at the times indicated.
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that in MG178 or U251MG cells
To assess why CD109 expression affects TGF-b1 and EGF
signaling only in SK-MG-1 cells, CD109 expression in SK-MG-1,
U251MG and MG178 cells was analyzed with western blotting.
Variable forms of cellular CD109 protein are summarized in Fig. 1B
[16]. Two CD109 fragments of 180 and 190 kDa were detected in
whole cell lysates using the anti-CD109 (C-9) antibody, whereas
two CD109 fragments of 190 and 25 kDa were detected using the
anti-CD109 (11H3) antibody (Fig. 2A). The 180-kDa band represents
the membrane-anchored N-terminal fragment, the 25-kDa band
represents the GPI-anchored C-terminal fragment, and the 190-kDa
band represents cytosolic, immature, uncleaved CD109 (Fig. 1B).
Interestingly, the endogenous 180-kDa fragment of CD109 in SK-
MG-1 cell lysate was a little larger compared with that in
U251MG or MG178 (Fig. 2A). FLAG-CD109-overexpressing cell ly-
sates were also subjected to western blotting and immunoprecip-
itation with anti-FLAG antibody. The expression pattern of
exogenous FLAG-CD109 in these cells was similar to that of
endogenous CD109 (Fig. 2B, C). Secreted 180 kDa CD109 in the
conditioned media was detected by immunoprecipitation and
western blotting using the anti-FLAG antibody. The secretedfragment was also a little larger in SK-MG-1 compared with that in
U251MG or MG178 (Fig. 2D).
To assess the structural difference between the 180-kDa CD109
fragment in SK-MG-1 and that in U251MG or MG178, the three cell
lines were treated with tunicamycin, a glycosylation inhibitor, for
48 h, and their cell lysates were then subjected to western blotting.
After the treatment, all of the 190-kDa fragments shifted to approx-
imately 150 kDa,whereas 180- and 25-kDa fragments did not change
their size but their amounts were reduced (Fig. 2E). This ﬁnding
suggests that 150-kDa fragment represents cytosolic uncleaved
CD109 without glycosylation, and the 180- and 25-kDa fragments
represent the residual undegraded fragments. Next, we treated
immunoprecipitated FLAG-CD109 of SK-MG-1-CD109, U251MG-
CD109 and MG178-CD109 cells with PNGase F, which cleaves
asparagine-linked oligosaccharides from glycoproteins, and the
deglycosylated FLAG-CD109 was assessed by western blotting. Two
bands, approximately 150 and 130 kDa,were detected by anti-CD109
(C-9) antibody, in which the 150- and 130-kDa fragments might
represent deglycosylated, cytosolic, uncleaved CD109 and deglyco-
sylated, membrane-anchored CD109, respectively (Fig. 2F). The sizes
of these deglycosylated fragments were similar among the three cell
lines. These results indicate that the 180-kDa CD109 in SK-MG-1 is
hyperglycosylated compared with that in MG178 or U251MG.
Fig. 2. Endogenous and exogenous CD109 expression in SK-MG-1, MG178 and U251MG cells, and glycosylation analyses of CD109. (A) Western blot analyses for endogenous CD109
expression in SK-MG-1, MG178 and U251MG. (B) Western blot analyses for exogenous CD109 expression in SK-MG-1, MG178, and U251MG overexpressing FLAG-CD109. (C)
Immunoprecipitation analysis of CD109. FLAG-CD109 in each cell lysate was immunoprecipitated with anti-FLAG antibody and control IgG, followed by western blotting with anti-
FLAG antibody. (D) Secreted CD109 in conditioned media. The conditioned media of SK-MG-1, MG178, and U251MG overexpressing FLAG-CD109 were subjected to immunopre-
cipitation and western blotting with anti-FLAG antibody. (E) Inhibition of CD109 glycosylation. SK-MG-1, MG178 and U251MG were treated with 2 mg/ml tunicamycin for 48 h, and
whole cell lysates from treated and untreated cells were subjected to western blotting. (F) Deglycosylation of CD109. FLAG-CD109 isolated from FLAG-CD109-expressing SK-MG-1,
MG178 and U251MG by immunoprecipitation with anti-FLAG antibody was treated with PNGase F for 3 h, and treated and untreated FLAG-CD109 was subjected to western blotting.
Closed arrowhead; 190-kDa CD109, open arrowhead; 180-kDa CD109, gray arrow; unglycosylated, uncleaved CD109, closed arrow; deglycosylated, uncleaved CD109, open arrow;
deglycosylated, cleaved CD109.
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signaling but not EGF signaling
Since it has been reported that the secreted N-terminal frag-
ment of CD109 is important for TGF-b1 signal modulation, we nextexamined whether the N-terminal CD109 fragment secreted from
SK-MG-1 is associated with EGF signal enhancement as well as
TGF-b1 signal attenuation. When wild-type SK-MG-1 were stimu-
lated with TGF-b1 in SK-MG-1-CD109 conditioned media, SMAD2
phosphorylation was attenuated compared with stimulation in SK-
J.-M. Zhang et al. / Biochemical and Biophysical Research Communications 459 (2015) 252e258256MG-1-control conditioned media, as expected (Fig. 3A). The signal
attenuation was also observed when wild-type MG178 were
stimulated with TGF-b1 in the same way. In contrast, when wild-
type SK-MG-1 and MG178 were stimulated with TGF-b1 in
MG178-CD109 conditioned media, the signal modulation was not
observed (Fig. 3B). These results suggest that the N-terminal CD109
fragment secreted from SK-MG-1-CD109 cells, but not from
MG178-CD109 cells, modulates TGF-b1 signaling. We also exam-
ined the ability of the secreted CD109 from SK-MG-1-CD109 cells to
modulate EGF signaling; however, EGF signal modulation in wild-
type SK-MG-1 was not observed after EGF stimulation (Fig. 3C).
These results indicate that secreted CD109 may play a role in TGF-
b1 signal attenuation but not for EGF signal enhancement, and that
themechanism of EGF signal modulation by CD109 is different from
that of TGF-b1 signal modulation.3.4. CD109 interacts with the EGF receptor in SK-MG-1 cells
In this study, we observed a novel ﬁnding that CD109 is involved
in EGF signaling in SK-MG-1. To elucidate themolecular mechanism
of CD109 involvement in the EGF signaling pathway in SK-MG-1, we
assessed the interaction between CD109 and EGFR. When FLAG-
CD109 was immunoprecipitated from SK-MG-1-CD109 cell lysate
with anti-FLAG antibody, endogenous EGFR was co-precipitated
(Fig. 4A). The amount of EGFR co-precipitated with FLAG-CD109
was reduced after EGF stimulation. Co-precipitated EGFR was
hardly detected when MG178-CD109 or U251MG-CD109 cell ly-
sates were used for the co-immunoprecipitation analysis (data not
shown).
We further assessed the intracellular localization of CD109
and EGFR in SK-MG-1-CD109 cells by immunocytochemistryFig. 3. Secreted CD109 from SK-MG-1 cells modulates TGF-b1 signaling, but not EGF signa
inhibited TGF-b1 signaling. Wild-type SK-MG-1 and MG178 cells were stimulated with 50 p
and MG178-CD109 or MG178-control cells (B) for the indicated times, and phosphorylation
cells did not enhance EGF signaling. Wild-type SK-MG-1 and MG178 cells were stimulated w
cells for the indicated times, and phosphorylation of EGFR was assessed by western blottin(Supplementary Doc S1). FLAG-CD109 was localized to the
plasma membrane and colocalized with EGFR in the absence of
EGF stimulation (Fig. 4B). Ten minutes after EGF stimulation, the
majority of EGFR was internalized to the cytoplasm; however,
CD109 was still on the plasma membrane and colocalized with a
small fraction of EGFR (Fig. 4B). No apparent difference in EGFR
internalization was observed between SK-MG-1-CD109 and SK-
MG-1-control cells. These results indicate that CD109 interacts
with EGFR in the absence of EGF stimulation and that the
interaction might be abolished upon phosphorylation of EGFR by
EGF stimulation; furthermore CD109 does not affect EGFR
internalization.3.5. CD109 enhances migration and invasion of SK-MG-1 cells
Last, we assessed the effect of CD109 on motility of SK-MG-1. In
the in vitrowound-healing assay, SK-MG-1-CD109 cells migrated to
the wound area much faster than SK-MG-1-control cells (Fig. 4C).
The SK-MG-1-CD109 wound was almost closed 22 h after
scratching, whereas the SK-MG-1-control wound was still a
considerable size. The counts of migrated SK-MG-1-CD109 cells
were signiﬁcantly higher compared with those of SK-MG-1-control
cells in the Boyden Chamber assay (Fig. 4D). We then analyzed the
invasion ability of SK-MG-1-CD109 and SK-MG-1-control cells.
Fig. 4E shows the images of ﬂuorescence-labeled cells that had
invaded to the underside of the Boyden Chamber membrane
through the matrigel matrix. The counts of invaded SK-MG-1-
CD109 cells were higher than those of SK-MG-1-control cells
(Fig. 4F), demonstrating that CD109-overexpressing SK-MG-1
invaded much faster than control cells. These results indicate that
CD109 facilitates motility in SK-MG-1.ling. (A, B) FLAG-CD109 secreted from SK-MG-1-CD109, but not from MG178-CD109,
M TGF-b1 in the conditioned media from SK-MG-1-CD109 or SK-MG-1-control cells (A)
of SMAD2 was assessed by western blotting. (C) FLAG-CD109 secreted from SK-MG-1
ith 10 ng/ml EGF in the conditioned media from SK-MG-1-CD109 or SK-MG-1-control
g.
Fig. 4. CD109 interacts with EGF receptor and enhances cell migration and invasion in SK-MG-1 cells. (A) CD109 interacts with EGFR. Cell lysates from SK-MG-1-CD109 cells with or
without EGF stimulation (25 ng/ml, for 15 min) were subjected to immunoprecipitation with anti-FLAG antibody and control IgG followed by western blotting. (B) CD109 colocalizes
with EGFR in the absence of EGF stimulation. SK-MG-1-CD109 and SK-MG-1-control cells with or without EGF stimulation (25 ng/ml, for 10 min) were ﬂuorescently double-
immunostained with rabbit anti-EGFR and mouse anti-FLAG antibodies (Supplementary Doc S1). Scale bars indicate 20 mm in length. (C, D) CD109 enhances cell migration. (C)
SK-MG-1-CD109 and SK-MG-1-control cells were subjected to the wound-healing assay, and cell images were captured at 0, 8 and 22 h after commencing the assay. (D) Two stable
SK-MG-1-CD109 and SK-MG-1-control clones were subjected to an in vitro migration assay. The number of migrated SK-MG-1-control #1 cells was deﬁned as 1.0. *p < 0.05. (E, F)
CD109 enhances cell invasion ability. (E) Images of invaded SK-MG-1-control and SK-MG-1-CD109 cells. (F) Relative number of invaded cells for each cell line is shown. The number
of invaded SK-MG-1-control #1 cells is deﬁned as 1.0. **p < 0.05.
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Several genetic and epigenetic alterations are involved in glio-
blastoma development [21,22]. EGFR ampliﬁcation and over-
expression are detected in approximately 40% and more than 60%
of primary glioblastomas, respectively. A mutated EGFR transcript,
EGFRvIII, in which exons 2e7 are deleted, is present in 20e50% of
glioblastomas with EGFR ampliﬁcation. The EGFRvIII protein lack-
ing the ligand-binding domain is constitutively activated without
ligand stimulation, and enhances cell proliferation through the
PI3K/AKT pathway. Thus, signaling status through EGFR is a crucial
factor in the pathogenesis of glioblastoma.
We and others have previously detected CD109 expression in
human glioblastoma cells by northern blot and RT-PCR analyses
[5,23]. We aimed to investigate the signiﬁcance of CD109 expres-
sion in glioblastoma cells. We showed that CD109 enhances EGF
signaling in SK-MG-1 cells via amechanism that is different from its
involvement in TGF-b1 signaling. In addition, CD109 facilitated cell
migration and invasion in SK-MG-1. These results suggest that
CD109 is associated with tumorigenesis in a portion of glioblas-
tomas. EGFR alterations are detected in many kinds of cancer,
including non-small cell lung cancers, head and neck SCCs, renal
cell carcinomas, breast cancers, and gastrointestinal cancers
[24e27], and CD109 is highly expressed in several cancers, espe-
cially SCCs [6e12]. However, the signiﬁcance of CD109 in cancer
biology is unclear. The present results demonstrate that CD109 is
associated with growth factor signaling in glioblastoma, which
might be applicable to other cancers expressing CD109.It is revealed that the effect of CD109 on EGF and TGF-b1
signaling is cell-type dependent in glioblastoma cells. CD109
enhanced EGF signaling and attenuated TGF-b1 signaling in SK-
MG-1, but not in MG178 and U251MG. In addition, N-terminal
CD109-containing conditioned media from SK-MG-1-CD109 cells
induced TGF-b1 signal attenuation in wild-type SK-MG-1 and
MG178, whereas that from MG178-CD109 cells did not. The N-
terminal fragment of CD109 in SK-MG-1 is hyperglycosylated
compared with that in MG178 or U251MG. These results suggest
that CD109 activity on EGF and TGF-b1 signaling may be associated
with glycosylation of the N-terminal CD109 fragment. CD109 shows
various glycosylation levels dependent on tissues or tumor cells [Y.
Murakumo, unpublished data, [20,28]], which suggests that CD109
activity may be diverse in various tumor cells. A recent publication
reported that variability of vascular endothelial growth factor
(VEGF)-targeted therapies is dependent on glycosylation status of
the endothelial cells [29]. They showed that anti-VEGF-sensitive
tumors exhibit high levels of a2-6-linked sialic acid on tumor
vessels, which inhibits galectin-1 binding to endothelial cells.
Meanwhile anti-VEGF-refractory tumors show decreased a2-6-
linked sialylation in tumor-associated vasculature, which facili-
tates VEGFR2 activation and confers resistance to anti-VEGF ther-
apy. Therefore, it is possible that the glycosylation diversity of
CD109 might be associated with glioblastoma biology and the
therapeutic effect of EGFR targeting therapy.
CD109 is cleaved by furin and a fraction of the resultant N-ter-
minal fragment of CD109 is secreted from cells; the rest remains on
the cell surface. Expression of the soluble form of CD109 attenuated
J.-M. Zhang et al. / Biochemical and Biophysical Research Communications 459 (2015) 252e258258TGF-b1 signaling in HEK293 cells, and addition of recombinant
soluble CD109 to culture media attenuated TGF-b1 signaling and
enhanced phosphorylation of STAT3 [16,18], indicating that the
secreted form of CD109 is important for signal transduction in the
TGF-b1 and STAT pathways. Compatible with these previous re-
ports, we demonstrated a negative effect of the secreted N-terminal
CD109 fragment in TGF-b1 signaling; however, it did not modulate
EGF signaling. In addition, we demonstrated that the membrane-
anchored N-terminal CD109 fragment interacts with EGFR, sug-
gesting that membrane-anchored N-terminal CD109 may play an
important role in EGF signal enhancement. In the TGF-b1 signaling
pathway, it is supposed that secreted CD109 binds to TGF-b1 and
then binds toTGF-b receptor I and II forming a receptor complex for
TGF-b1 signal transduction [13]. In the EGF signaling pathway, we
propose that CD109 on the cell surface forms a complex with EGFR
and enhances phosphorylation of EGFR upon EGF stimulation, and
that the interaction between CD109 and EGFR is abolished after EGF
stimulation. Thus, CD109 in SK-MG-1 cells is involved in both TGF-
b1 and EGF signaling through different processes, using secreted
CD109 andmembrane-anchored CD109, respectively; both forms of
CD109 play important roles in cell biology.
In conclusion, our results indicate that CD109 is involved in both
EGF and TGF-b1 signaling, two major molecular pathways in hu-
man glioblastoma development. A precise elucidation of the effect
of CD109 on EGF and TGF-b signaling is necessary for under-
standing glioblastoma biology.
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